EUnetHTA Joint Action 3 WP4: Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
- Publication date:
- 12 March 2020
This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national requirements of EUnetHTA partners.